Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Nucl Med Biol. 2012 Dec 23;40(2):245–251. doi: 10.1016/j.nucmedbio.2012.10.010

Figure 3.

Figure 3

Percentage of α4(VLA-4)positive cells in total B16F10 tumor cell population as determined by flow cytometry (Anti-Mouse CD49d (integrin a-4) (eBioscience). Greater than 99% cells were positive for VLA-4 (A). The binding of 64Cu-CB-TE1A1P-LLP2A and 64Cu-CB-TE2A-LLP2A to integrin α4β1 was determined by a saturation binding assay in B16F10 melanoma cells (n=3 for each data point; mean value ± SE). The Kd for 64Cu-CB-TE1A1P-LLP2A and 64Cu-CB-TE2A-LLP2A are 1.2 ± 0.2 nM and 1.6 ± 0.4 nM, respectively. The receptor concentrations (Bmax) for 64Cu-CB-TE1A1P-LLP2A and 64Cu-CB-TE2A-LLP2A are 471 ± 14 and 304 ± 18 fmol/mg, respectively (p< 0.03).